Barinthus Biotherapeutics plc. (BRNS) Latest Filing Signal
Cross-checked across multiple AI analysts and grounded in the latest SEC filing.
powered by: earningsVibe.ai
Question:
What is the latest filing signal for Barinthus Biotherapeutics plc.?
Answer:
Based on earningsVibe SuperAnalyst™ synthesis of the latest
10-K, Barinthus Biotherapeutics plc.'s filing signal
turned negative.
earningsVibe SuperAnalyst™ Verdict:
TURNED NEGATIVE
Signal Performance — Stock Price Since Filing
30-Day Change
Pending
from filing date
60-Day Change
Pending
from filing date
Underlying analyst views from Perplexity, Gemini, Claude, and ChatGPT
PERPLEXITY
Continuing Negative
GEMINI
Turned Negative
CLAUDE
Turned Negative
CHATGPT
Continuing Negative
Unlock the Full Filing Analysis
See full earningsSig™ and risksSig™ analysis across 5,000+ companies
Get Started Free →No credit card required
Question:
What does Barinthus Biotherapeutics plc. actually do?
Answer:
Barinthus Biotherapeutics plc is a clinical-stage biopharmaceutical company focused on developing novel immunotherapeutic drug candidates for autoimmune and inflammatory diseases. The company's proprietary SNAP-TI platform aims to guide T cells to reduce inflammation and restore immune tolerance, with its lead candidate, VTP-1000, targeting celiac disease and currently in Phase 1 clinical trials. Barinthus Bio is also exploring partnerships for VTP-300, a viral vector-based immunotherapy for chronic hepatitis B. In 2025, the company underwent a strategic refocus, deprioritizing certain programs and reducing its workforce by approximately 65% to extend its cash runway. Barinthus Bio is also pursuing a combination transaction with Clywedog Therapeutics, Inc., expected to close in the second quarter of 2026.
Question:
What are Barinthus Biotherapeutics plc.'s revenue drivers?
Answer:
Historically, revenue has been driven by license and royalty payments related to the Vaxzevria vaccine, though this revenue ceased in 2025. The company does not currently generate revenue from product sales and anticipates future revenue from potential commercialization of its product candidates.
Cut through noisy SEC filings to find the signal faster
Source-grounded filing intelligence with one-click links back to the filing, so you can move faster and verify everything at the source.
Get Started Free →No credit card required